BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 322460)

  • 21. [Not Available].
    CEDEF
    Ann Dermatol Venereol; 2018 Mar; 145 Suppl 1():S165-S185. PubMed ID: 29475619
    [No Abstract]   [Full Text] [Related]  

  • 22. Letter: Malignant melanoma arising de novo within a B.C.G. scarification site.
    Lokich JJ
    Lancet; 1975 Feb; 1(7902):331-2. PubMed ID: 46469
    [No Abstract]   [Full Text] [Related]  

  • 23. Long-term spontaneous regression of malignant melanoma with visceral metastases. Report of a case with immunologic profile.
    Bulkley GB; Cohen MH; Banks PM; Char DH; Ketcham AS
    Cancer; 1975 Aug; 36(2):485-94. PubMed ID: 1157014
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Progress in melanoma histopathology and diagnosis.
    Piris A; Mihm MC
    Hematol Oncol Clin North Am; 2009 Jun; 23(3):467-80, viii. PubMed ID: 19464597
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Etiopathogenesis of malignant melanoma of the skin. I. Clinico-biological and nosologic considerations].
    Nigro MA; Castellani L; Chieregato C
    G Ital Dermatol Venereol; 1990 Mar; 125(3):105-9. PubMed ID: 2198227
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Skin types in dysplastic nevus syndrome.
    Kopf AW; Goldman RJ; Rivers JK; Levenstein M; Rigel DS; Friedman RJ; Bart RS
    J Dermatol Surg Oncol; 1988 Aug; 14(8):827-31. PubMed ID: 3397442
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Immunotherapy for human malignant melanoma.
    Kopf AW
    South Med J; 1975 Apr; 68(4):495-503. PubMed ID: 1124416
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cancer immunotherapy: an overview.
    Morton DL
    Semin Oncol; 1974 Dec; 1(4):297-310. PubMed ID: 4620437
    [No Abstract]   [Full Text] [Related]  

  • 29. Sequential studies on cell-mediated tumor immunity and blocking serum activity in ten patients with malignant melanoma.
    Hellström I; Warner GA; Hellström KE; Sjögren HO
    Int J Cancer; 1973 Mar; 11(2):280-92. PubMed ID: 4790696
    [No Abstract]   [Full Text] [Related]  

  • 30. Active specific and active non-specific immunotherapy in patients with malignant melanoma.
    Kokoschka EM; Cerni C; Micksche M
    Oncology; 1977; 34(5):229-33. PubMed ID: 917456
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The characterization of tumour-associated membrane-bound antigens and their implementation in the treatment of malignant melanoma (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr Suppl; 1979; 97():3-32. PubMed ID: 106559
    [No Abstract]   [Full Text] [Related]  

  • 32. Melanocytes of a melanocytic nevus in a lymph node from a patient with a primary cutaneous melanoma associated with a small congenital nevus.
    Hruban RH; Eckert F; Baricević B
    Am J Dermatopathol; 1990 Aug; 12(4):402-7. PubMed ID: 2203272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A classification of melanocytic dysplasias and malignant melanomas.
    Reed RJ
    Am J Dermatopathol; 1984; 6 Suppl():195-206. PubMed ID: 6528920
    [No Abstract]   [Full Text] [Related]  

  • 34. Viral oncolysate in the management of malignant melanoma. I. Preparation of the oncolysate and measurement of immunologic responses.
    Cassel WA; Murray DR; Torbin AH; Olkowski ZL; Moore ME
    Cancer; 1977 Aug; 40(2):672-9. PubMed ID: 196739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Immunology of malignant melanoma (author's transl)].
    Macher E; Sorg C; Seibert Er
    Langenbecks Arch Chir; 1976 Nov; 342():533-8. PubMed ID: 994670
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Immunological conditions in patients with malignant melanoma of the skin].
    Kristensen E
    Ugeskr Laeger; 1976 Feb; 138(8):463-8. PubMed ID: 1258214
    [No Abstract]   [Full Text] [Related]  

  • 37. Biology of tumor progression in human melanocytes.
    Herlyn M; Clark WH; Rodeck U; Mancianti ML; Jambrosic J; Koprowski H
    Lab Invest; 1987 May; 56(5):461-74. PubMed ID: 3553733
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor progression in the human melanocytic system.
    Kath R; Rodeck U; Menssen HD; Mancianti ML; Linnenbach AJ; Elder DE; Herlyn M
    Anticancer Res; 1989; 9(4):865-72. PubMed ID: 2554787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Immunological aspects of melanoma].
    Sjögren H
    Lakartidningen; 1976 Feb; 73(7):528-30. PubMed ID: 1250045
    [No Abstract]   [Full Text] [Related]  

  • 40. Dysplasia, dysplastic melanocytes, dysplastic nevi, the dysplastic nevus syndrome, and the relation between dysplastic nevi and malignant melanomas.
    Ackerman AB; Mihara I
    Hum Pathol; 1985 Jan; 16(1):87-91. PubMed ID: 3972389
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.